1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
| Autor: | Garcia Campelo, M.R., Felip, E., Besse, B., Cobo Dols, M., Quoix, E., Madroszyk Flandin, A-C., Cappuzzo, F., Denis, F., Hilgers, W., Romano, G., Debieuvre, D., Galetta, D., Baldini, E., Viteri Ramirez, S., Duc Phan, M., Schuette, W., Zer, A., Vasseur, B., Dziadziuszko, R., Giaccone, G. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1020-S1020 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|